Ipca Laboratories (NSE:IPCALAB) Beta: 0.1681 (As of Jun. 26, 2026)


NSE:IPCALAB Ipca Laboratories Ltd NSE:IPCALAB
86 GF Score
Price ₹1,618.30
GF Value ₹1,594.77
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Ipca Laboratories Beta?

Ipca Laboratories NSE:IPCALAB -0.18% 86 Beta is 0.1681 as of Jun. 26, 2026. GuruFocus rates NSE:IPCALAB with a GF Score™ of 86/100 and a GF Value™ of ₹1,594.77 (Fairly Valued). The stock has 4 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Ipca Laboratories's Beta is 0.1681.


Ipca Laboratories  (NSE:IPCALAB) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Ipca Laboratories Beta Related Terms


Ipca Laboratories Beta Historical Data

* Premium members only.

The historical data trend for Ipca Laboratories's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ipca Laboratories Beta Chart

Ipca Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.33 0.85 0.78 0.58 0.15

Ipca Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.58 0.40 0.35 0.39 0.15

NSE:IPCALAB vs ZTS: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Ipca Laboratories's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ipca Laboratories Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ipca Laboratories's Beta distribution charts can be found below:

* The bar in red indicates where Ipca Laboratories's Beta falls into.


NSE:IPCALAB
86GF Score
Ipca Laboratories Ltd NSE:IPCALAB
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ipca Laboratories Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.1681 mean?
Ipca Laboratories (NSE:IPCALAB) has a Beta of 0.1681 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Ipca Laboratories and its competitors.
Is Ipca Laboratories' Beta too high?
Ipca Laboratories' current Beta is 0.1681. Overall, Ipca Laboratories has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ipca Laboratories' Beta compare to ZTS?
Ipca Laboratories' Beta of 0.1681 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Ipca Laboratories and its competitors. Ipca Laboratories's current Beta is 0.1681. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ipca Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Ipca Laboratories (NSE:IPCALAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,594.77, compared to a current price of ₹1,618.30 — trading 1.5% above its estimated fair value. The current Beta is 0.1681. Ipca Laboratories' overall GF Score™ is 86/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Ipca Laboratories (NSE:IPCALAB), the current Beta is 0.1681 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ipca Laboratories (NSE:IPCALAB) Overvalued in 2026?

Based on GuruFocus' analysis, Ipca Laboratories stock appears to be overvalued. The current stock price of ₹1,618.30 is trading 1.5% above its estimated GF Value™ of ₹1,594.77. GuruFocus considers Ipca Laboratories to be Fairly Valued.

Key valuation signals for NSE:IPCALAB:

  • Beta: 0.1681
  • GF Value™: ₹1,594.77 vs. price of ₹1,618.30 (1.5% above fair value)
  • GF Score™: 86/100 with 4 warning signs

No single metric tells the full story. See the NSE:IPCALAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ipca Laboratories Business Description

Other Exchanges 524494:India
Address No. 48, 123 AB, 125 & 126 Kandivli Industrial Estate, Kandivli (West), Mumbai, MH, IND, 400067
Ipca Laboratories Ltd is a pharmaceutical company. The company's principal activity is the Development, Manufacturing, and Marketing of Pharmaceuticals Products. The company's API products include Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), Losartan. The company has only one reportable primary business segment, pharmaceuticals.
86GF Score

Get the complete analysis for NSE:IPCALAB

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,618.30
Price
₹1,594.77
GF Value